CTNM · Contineum Therapeutics, Inc.
$17.19
+1.17 (+7.30%)
At close · Aug 21
Market Cap
$646.71M
Shares
37.62M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$0
-100%
FY2024
Net Income
-$59.98M
-41.9%
FY2025
Operating Margin
32.15%
FY2023
Diluted EPS
-$2.17
+0.5%
FY2025
Operating Cash Flow
-$55.31M
-68.4%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| — | — | $0 | $50M | |
| $48.1M | $51.52M | $38.42M | $27.6M | |
| $18.28M | $16.54M | $12.47M | $6.32M | |
| — | $323K | $258K | $195K | |
| $66.38M | $68.06M | $50.89M | $33.92M | |
| -$66.38M | -$68.06M | -$50.89M | $16.08M | |
| — | — | — | 32.15% | |
| — | -$67.74M | -$50.64M | $16.27M | |
| — | — | $0 | $208K | |
| $8.81M | $8.25M | $8.91M | $4.61M | |
| $8.82M | $8.08M | $8.64M | $7.09M | |
| — | -$60.14M | -$42.26M | $23.17M | |
| — | $0 | $0 | $450K | |
| -$57.56M | -$59.98M | -$42.26M | $22.72M | |
| — | — | — | 45.44% | |
| -$59.39M | — | -$42.26M | $3.15M | |
| -$58.28M | -$59.79M | -$42.3M | $22.9M | |
| USD/shares | — | -$2.17 | -$2.18 | $1.36 |
| USD/shares | — | -$2.17 | -$2.18 | $0.08 |
| shares | — | 27.7M | 19.35M | 2.31M |
| shares | — | 27.7M | 19.35M | 3.4M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 5.18×
EV/EBIT
—
Peer median 23.49×
P/E (TTM)
—
Peer median 13.23×
Peer medians compare against the 319 similar-size Biotechnology companies (of 545 listed).
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 |
|---|---|---|
| Reportable Segment | -$68,059,000 | -$50,894,000 |
Key facts
CIK
1855175
CUSIP
21217B100
13F (30d)
98 filings
96 filers
Visit website
Investor relations